Based in Durham, North Carolina, Eno River Capital focuses on investing in healthcare technology systems, pharmaceuticals, biotechnology, and TMT sectors. The fund typically invests between $1 million to $5 million in startups that are 2-3 years old. Eno River Capital has a higher exit rate compared to other companies and performs 4 percentage points above the average in lead investments. The fund has a strong presence in the United States and has invested in startups such as Blue292. It often co-invests with Wakefield Group, Noro-Moseley Partners, and has received funding from Sprout Group, Donaldson, Lufkin & Jenrette in subsequent rounds.